Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT
false
קמהדע בע"מ
2
380
KAMADA LTD
Corporation no:
511524605
14096
Israel Securities Authority
Tel Aviv Stock Exchange
C002
(
Public
)
Reported via MAGNA:
07/11/2022
www.isa.gov.il
www.tase.co.il
Reference:
2022-02-107820
Time of broadcast:
13:39
13:39
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT
ea168135-6k_kamadaEDGAR1_Bannerless_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
TASE
Date of revision of form structure:
02/11/2022
Address:
Holtzman 2
4081
,
Rehovot
7670402
ISRAEL
,
Tel:
08-9406472
,
Fax:
08-9406473
E-mail address:
liorf@kamada.com
Company site:
www.kamada.com
Previous names of reporting entity:
Name of the Signatory:
REFAEL MOSHE
Position of Signatory in the reporting corporation:
Company Controller
Name of Employer Company:
Address:
Holtzman
2
,
Rehovot
7670402
Telephone:
08-9406472
Facsimile:
08-9406473
E-mail:
mosheb@kamada.com
1